287 related articles for article (PubMed ID: 3335821)
1. Preservation of in vitro function of platelets stored in the presence of inhibitors of platelet activation and a specific inhibitor of thrombin.
Bode AP; Miller DT
J Lab Clin Med; 1988 Jan; 111(1):118-24. PubMed ID: 3335821
[TBL] [Abstract][Full Text] [Related]
2. The use of thrombin inhibitors and aprotinin in the preservation of platelets stored for transfusion.
Bode AP; Miller DT
J Lab Clin Med; 1989 Jun; 113(6):753-8. PubMed ID: 2471765
[TBL] [Abstract][Full Text] [Related]
3. Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma.
Zhang JG; Carter CJ; Culibrk B; Devine DV; Levin E; Scammell K; Weiss S; Gyongyossy-Issa MI
Transfusion; 2008 May; 48(5):847-56. PubMed ID: 18298601
[TBL] [Abstract][Full Text] [Related]
4. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
[TBL] [Abstract][Full Text] [Related]
5. Lipid peroxidation compared in stored whole blood with various nutrient-anticoagulant solutions.
Knight JA; Searles DA; Blaylock RC
Ann Clin Lab Sci; 1993; 23(3):178-83. PubMed ID: 8323251
[TBL] [Abstract][Full Text] [Related]
6. Room temperature storage and cryopreservation of canine platelet concentrates.
Allyson K; Abrams-Ogg AC; Johnstone IB
Am J Vet Res; 1997 Nov; 58(11):1338-47. PubMed ID: 9361903
[TBL] [Abstract][Full Text] [Related]
7. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days.
Shanwell A; Diedrich B; Falker C; Jansson B; Sandgren P; Sundkvist L; Svensson L; Vesterinen M; Gulliksson H
Transfusion; 2006 Jun; 46(6):973-9. PubMed ID: 16734814
[TBL] [Abstract][Full Text] [Related]
8. The use of inhibitors of platelet activation or protease activity in platelet concentrates stored for transfusion.
Bode AP; Norris HT
Blood Cells; 1992; 18(3):361-80; discussion 381-2. PubMed ID: 1337481
[TBL] [Abstract][Full Text] [Related]
9. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
10. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.
Apelseth TØ; Bruserud Ø; Wentzel-Larsen T; Bakken AM; Bjørsvik S; Hervig T
Transfusion; 2007 Apr; 47(4):653-65. PubMed ID: 17381624
[TBL] [Abstract][Full Text] [Related]
12. Storage of buffy-coat-derived platelets in additive solutions: in vitro effects on platelets stored in reformulated PAS supplied by a 20% plasma carry-over.
Sandgren P; Mayaudon V; Payrat JM; Sjödin A; Gulliksson H
Vox Sang; 2010 Apr; 98(3 Pt 2):415-22. PubMed ID: 19788514
[TBL] [Abstract][Full Text] [Related]
13. The quality of platelet concentrates produced by COBE Spectra and Trima Accel cell separators during storage for 7 days as assessed by in vitro methods.
Tynngård N; Lindahl TL; Trinks M; Studer M; Berlin G
Transfusion; 2008 Apr; 48(4):715-22. PubMed ID: 18208416
[TBL] [Abstract][Full Text] [Related]
14. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
15. Platelet additive solutions: a future perspective.
van der Meer PF
Transfus Clin Biol; 2007 Dec; 14(6):522-5. PubMed ID: 18420439
[TBL] [Abstract][Full Text] [Related]
16. Storage of buffy-coat-derived platelets in additive solutions at 4 degrees C and 22 degrees C: flow cytometry analysis of platelet glycoprotein expression.
Sandgren P; Hansson M; Gulliksson H; Shanwell A
Vox Sang; 2007 Jul; 93(1):27-36. PubMed ID: 17547562
[TBL] [Abstract][Full Text] [Related]
17. Platelet activation may explain the storage lesion in platelet concentrates.
Bode AP
Blood Cells; 1990; 16(1):109-25; discussion 125-6. PubMed ID: 2190643
[TBL] [Abstract][Full Text] [Related]
18. The effect of ASA on platelet activation during apheresis and on in-vitro properties of stored platelet concentrates.
Zeiler T; Gritzka D; Karger R; Kretschmer V
Transfusion; 2004 Sep; 44(9):1300-5. PubMed ID: 15318852
[TBL] [Abstract][Full Text] [Related]
19. Storage of red blood cells with improved maintenance of 2,3-bisphosphoglycerate.
Högman CF; Löf H; Meryman HT
Transfusion; 2006 Sep; 46(9):1543-52. PubMed ID: 16965582
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
Moog R; Fröhlich A; Mayaudon V; Lin L
J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
